Great Lakes Advisors LLC Sells 17,283 Shares of Orthofix Medical Inc. (NASDAQ:OFIX)

Great Lakes Advisors LLC lessened its holdings in Orthofix Medical Inc. (NASDAQ:OFIX) by 7.0% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 229,274 shares of the medical device company’s stock after selling 17,283 shares during the quarter. Great Lakes Advisors LLC’s holdings in Orthofix Medical were worth $4,003,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of the business. Geode Capital Management LLC increased its stake in Orthofix Medical by 1.4% in the 3rd quarter. Geode Capital Management LLC now owns 839,189 shares of the medical device company’s stock worth $13,111,000 after buying an additional 11,559 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Orthofix Medical by 4.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 339,531 shares of the medical device company’s stock worth $5,928,000 after buying an additional 14,724 shares in the last quarter. Algert Global LLC increased its stake in Orthofix Medical by 25.6% in the 3rd quarter. Algert Global LLC now owns 214,445 shares of the medical device company’s stock worth $3,350,000 after buying an additional 43,753 shares in the last quarter. Barclays PLC increased its stake in Orthofix Medical by 38.8% in the 3rd quarter. Barclays PLC now owns 122,472 shares of the medical device company’s stock worth $1,912,000 after buying an additional 34,210 shares in the last quarter. Finally, HighVista Strategies LLC purchased a new stake in Orthofix Medical in the 3rd quarter worth $1,689,000. Hedge funds and other institutional investors own 89.76% of the company’s stock.

Orthofix Medical Trading Up 1.4 %

OFIX opened at $16.53 on Friday. The firm has a market cap of $645.03 million, a P/E ratio of -5.28 and a beta of 1.06. Orthofix Medical Inc. has a 12 month low of $12.08 and a 12 month high of $20.73. The company has a current ratio of 2.39, a quick ratio of 1.11 and a debt-to-equity ratio of 0.25. The stock has a 50-day moving average of $17.83 and a 200 day moving average of $17.39.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Roth Mkm reiterated a “buy” rating and issued a $22.00 price target on shares of Orthofix Medical in a research note on Wednesday, February 26th. StockNews.com upgraded Orthofix Medical from a “hold” rating to a “buy” rating in a research report on Tuesday, February 25th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $24.00 price objective on shares of Orthofix Medical in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $23.33.

Insider Buying and Selling

In related news, CFO Julie Andrews sold 4,655 shares of Orthofix Medical stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $17.89, for a total value of $83,277.95. Following the completion of the transaction, the chief financial officer now owns 28,312 shares in the company, valued at approximately $506,501.68. This trade represents a 14.12 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Massimo Calafiore sold 10,078 shares of Orthofix Medical stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $16.83, for a total value of $169,612.74. Following the completion of the transaction, the chief executive officer now owns 133,354 shares of the company’s stock, valued at approximately $2,244,347.82. This represents a 7.03 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 25,442 shares of company stock worth $436,883. Corporate insiders own 2.60% of the company’s stock.

Orthofix Medical Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.